Polar Capital LLP reduced its position in shares of Sientra Inc (NASDAQ:SIEN) by 9.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 903,900 shares of the medical instruments supplier’s stock after selling 96,100 shares during the period. Polar Capital LLP owned 3.16% of Sientra worth $11,489,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Sientra during the 4th quarter worth approximately $29,000. Bank of New York Mellon Corp boosted its holdings in shares of Sientra by 1.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 221,093 shares of the medical instruments supplier’s stock worth $5,280,000 after purchasing an additional 2,726 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Sientra by 18.8% during the 3rd quarter. Alliancebernstein L.P. now owns 21,500 shares of the medical instruments supplier’s stock worth $513,000 after purchasing an additional 3,400 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Sientra by 16.2% during the 2nd quarter. Bank of America Corp DE now owns 26,638 shares of the medical instruments supplier’s stock worth $519,000 after purchasing an additional 3,718 shares during the last quarter. Finally, Great West Life Assurance Co. Can acquired a new position in Sientra in the fourth quarter valued at approximately $64,000. Institutional investors own 92.79% of the company’s stock.
SIEN has been the topic of a number of recent analyst reports. Leerink Swann decreased their price objective on Sientra from $22.00 to $18.00 in a report on Wednesday. Stifel Nicolaus decreased their price objective on Sientra from $19.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday. Dougherty & Co decreased their price objective on Sientra from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday. Maxim Group upgraded Sientra from a “hold” rating to a “buy” rating in a report on Wednesday, December 19th. Finally, ValuEngine cut Sientra from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $19.50.
Shares of NASDAQ SIEN opened at $8.34 on Friday. The company has a market capitalization of $325.46 million, a price-to-earnings ratio of -2.57 and a beta of -0.04. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.34 and a current ratio of 2.77. Sientra Inc has a 52-week low of $7.74 and a 52-week high of $26.79.
Sientra (NASDAQ:SIEN) last announced its earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.19). The firm had revenue of $19.02 million during the quarter, compared to analysts’ expectations of $18.87 million. Sientra had a negative net margin of 121.28% and a negative return on equity of 123.50%. Analysts predict that Sientra Inc will post -2.52 earnings per share for the current fiscal year.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More: QQQ ETF
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.